Home 📚BioDBS Bibliography database[Title] Hepatobiliary disorders and Direct-Acting Antiviral (DAA) therapies: real-world evidence and insights from the EudraVigilance database

Hepatobiliary disorders and Direct-Acting Antiviral (DAA) therapies: real-world evidence and insights from the EudraVigilance database

database[Title] 2025-04-23

Summary:

CONCLUSION: Harvoni® showed a lower reporting frequency of hepatobiliary disorders and fewer drug ineffectiveness reports, suggesting it may be preferred over Epclusa® and Vosevi® in patients with preexisting liver or biliary conditions.

Link:

https://pubmed.ncbi.nlm.nih.gov/40243008/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=12QQbiNmM99eUQGIX1JjHIKcROC1Vzv4sOS-2S_LNI19uG_Yrk&fc=20220129225649&ff=20250422235854&v=2.18.0.post9+e462414

From feeds:

📚BioDBS Bibliography » database[Title]

Tags:

Authors:

John Scicluna, Raffaella Di Napoli, Daniele Pirozzi, Federica Fraenza, Mirko Cardillo, Cristina Scavone, Annalisa Capuano

Date tagged:

04/23/2025, 00:08

Date published:

04/17/2025, 06:00